Precision Biosensor Inc.
Precision Biosensor, Inc. engages in the development, production, and sale of immune diagnostic kits in South Korea. It offers Exdia TRF Plus, an immunodiagnosis POCT platform; and Exdia PT10 and Exdia PT10S, a clinical chemistry POCT platform. The company was founded in 2009 and is headquartered in Daejeon, South Korea.
Precision Biosensor Inc. (335810) - Total Assets
Latest total assets as of September 2025: ₩48.42 Billion KRW
Based on the latest financial reports, Precision Biosensor Inc. (335810) holds total assets worth ₩48.42 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Precision Biosensor Inc. - Total Assets Trend (2017–2024)
This chart illustrates how Precision Biosensor Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Precision Biosensor Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Precision Biosensor Inc.'s total assets of ₩48.42 Billion consist of 31.5% current assets and 68.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩1.72 Billion | 3.3% |
| Accounts Receivable | ₩1.95 Billion | 3.8% |
| Inventory | ₩8.99 Billion | 17.3% |
| Property, Plant & Equipment | ₩30.84 Billion | 59.3% |
| Intangible Assets | ₩2.68 Billion | 5.1% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Precision Biosensor Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Precision Biosensor Inc.'s current assets represent 31.5% of total assets in 2024, a decrease from 60.0% in 2017.
- Cash Position: Cash and equivalents constituted 3.3% of total assets in 2024, down from 3.4% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is property, plant & equipment at 59.3% of total assets.
Precision Biosensor Inc. Competitors by Total Assets
Key competitors of Precision Biosensor Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Precision Biosensor Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Precision Biosensor Inc. generates 0.37x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Precision Biosensor Inc. is currently not profitable relative to its asset base.
Precision Biosensor Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.62 | 2.89 | 8.45 |
| Quick Ratio | 0.25 | 1.41 | 7.23 |
| Cash Ratio | 0.00 | 0.36 | 0.00 |
| Working Capital | ₩-9.21 Billion | ₩ 10.85 Billion | ₩ 28.55 Billion |
Precision Biosensor Inc. - Advanced Valuation Insights
This section examines the relationship between Precision Biosensor Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.58 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -16.7% |
| Total Assets | ₩52.04 Billion |
| Market Capitalization | $6.02 Million USD |
Valuation Analysis
Below Book Valuation: The market values Precision Biosensor Inc.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Precision Biosensor Inc.'s assets decreased by 16.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Precision Biosensor Inc. (2017–2024)
The table below shows the annual total assets of Precision Biosensor Inc. from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩52.04 Billion | -16.71% |
| 2023-12-31 | ₩62.48 Billion | +5.88% |
| 2022-12-31 | ₩59.01 Billion | +5.91% |
| 2021-12-31 | ₩55.72 Billion | +31.79% |
| 2020-12-31 | ₩42.28 Billion | +98.97% |
| 2019-12-31 | ₩21.25 Billion | +70.83% |
| 2018-12-31 | ₩12.44 Billion | -19.35% |
| 2017-12-31 | ₩15.42 Billion | -- |